Kannalife, a subsidiary of Neuropathix, Inc, is a biopharmaceutical company focused on discovering, developing and commercializing a product platform of novel molecules from our proprietary next generation cannabinoid therapeutics as potent, non-opioid alternatives to treat patients with a variety of unmet medical needs. Since 2010, we have been principally involved in the research and development of synthetic cannabidiol (“CBD”) therapeutics through pre-clinical drug discovery and development processes. We have developed our own intellectual property portfolio and established relationships with globally recognized third parties who are considered leaders in active pharmaceutical (“API”) contract manufacturers, formulators and contract bulk drug manufacturers. From 2012 to 2019, Kannalife held an exclusive license with National Institutes of Health – Office of Technology Transfer (“NIH-OTT”) for the Commercialization of U.S. Patent #6630507, “Cannabinoids as Antioxidants and Neuroprotectants” (the “‘507 Patent”). Kannalife has also developed its own patented molecules lead by KLS-13019 called by Sports Illustrated as a “super-CBD” and was recently awarded U.S. Patent #9611213, “Functionalized 1,3-benzene diols and their method of use for the treatment of hepatic encephalopathy” and U.S. Patent #10004722, “Method for treating hepatic encephalopathy or a disease associated with free radical mediate stress and oxidative stress with novel functionalized 1,3-benzene diols.”

After careful pre-clinical evaluation of CBD, and understanding its PK/PD limitations, we began the process of new target drug candidate discovery. In 2015 we developed, tested in pre-clinical settings and patented an estate of cannabidiol-like NCE’s lead by KLS-13019 that significantly improved on the limitations of cannabidiol, focusing on increased bioavailability, potency and safety. Currently two of our patents have been granted in the U.S. (#9611213 & #10004722), a Japanese Patent JP6486950B2 and a Russian Patent RU2676475C2; this intellectual property is currently pending patent approval in the European Union, China, Australia, Brazil, India and Canada.

Kannalife Sciences has been awarded a total of $3,270,688 in study grants from the National Institutes of Health (NIH) to date. The company was awarded a $299,916 study grant in 2018 from National Institute of Drug Abuse (NIDA) to research KLS-13019 for its development in Chemotherapy Induced Peripheral Neuropathy and Drug Dependence and in 2021 was awarded $2.97M in a 3-year IND enabling study grant with National Institute of Neurological Disorders and Stroke (NINDS) to further research Development of KLS-13019 for Neuropathic Pain.

Kannalife is currently conducting research and development of our proprietary therapeutic platform at the Bucks County Pennsylvania Biotechnology Center in Doylestown, PA, for targeted drug candidates to treat Hepatic Encephalopathy (“HE”), Traumatic Brain Injury (“TBI”), Chronic Traumatic Encephalopathy (“CTE”), Radiation Dermatitis (“RD”) and Chemotherapy Induced Peripheral Neuropathy (“CIPN”). 

We are one of the leading companies focused on addressing neurodegenerative, oxidative Stress and neuropathic pain related diseases and related social issues: cannabis as a medicament, concussion related injuries like TBI and CTE, cancer treatment, neuropathic pain and the opioid crisis.